Conditions: Transgender Persons
Keywords: Testosterone, breast
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 5
Healthy volunteers: no

Brief summary:
* Purpose. The purpose of this research is study the effect of progesterone therapy on testosterone levels in transwomen who are currently on gender affirming treatment with estradiol.
* Duration. It is expected that participation will last for 6 months (24 weeks).
* Study Procedures. Participants will be asked to sign an informed consent, complete a medical history, have a physical exam conducted, have a fasting blood sample taken and asked to take a study drug once daily.
* Risks. Some of the foreseeable risks or discomforts include temporary discomfort, bleeding, bruising and/or swelling in the arm from blood draw. There are no known direct risks with the use of Progesterone in Transwomen for gender affirming therapy.
* Benefits. Some of the possible benefits that may be expected include increase in fat mass, increase in breast size/fullness, decrease in masculine hair patterns.

Detailed description:
The number of individuals with gender incongruence who present to their physician for hormone therapy has increased manifold in the last decade. Testosterone therapy in transgender men (also known as female-to-male transgender or transmen) and estrogen therapy in transgender women (also known as male-to-female transgender or transwomen) respectively is the mainstay of hormone regimen.Transwomen, who are genetically men, receive estradiol replacement with the aim of suppressing serum testosterone and achieving serum estradiol concentrations that mimic the serum concentrations of biological women. This leads to an increase in fat mass, breast growth and decreases in lean mass and masculine pattern hair. However, the results of these changes are often less than satisfactory and additional therapy is required.

Breast development is a major concern for transgender females. There is a great deal of variability among individuals, as evidenced during pubertal development.Transgender women do not achieve the same level of breast development as cisgender women do after puberty. Typically, transgender women plateau at Tanner stage III and half of the transgender women have a AAA cup size or less.Investigators plan to conduct a randomized, placebo controlled double blind study evaluating the effect of adding progesterone for 6 months to transwomen who are being treated with estradiol. The hypothesis is that progesterone will decrease serum testosterone concentrations as compared to placebo and increase breast size. Investigators will also assess its role in mood, sleep, scalp hair and androgenic hair growth.

Arms:
arm 1: subjects on active drug (progesterone) arm 2: subjects on placebo

Interventions: intervention 1: Progesterone 200 MG intervention 2: Placebo
Intervention descriptions: intervention 1: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily. intervention 2: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.

Protocol document:
Prot_SAP_001.pdf: 
Title: Effect of Progesterone on 
Testosterone concentrations and Breast 
development in Transwomen 
 
NCT04534881 
 
Date: 9/13/2020 
 
 
 
 


The number of individuals with gender incongruence who present to their physician for hormone 
therapy has increased manifold in the last decade(1). Testosterone therapy in transgender men (also 
known as female-to-male transgender or transmen) and estrogen therapy in transgender women (also 
known as male-to-female transgender or transwomen) respectively is the mainstay of hormone 
regimen. The proportion of individuals that are transwomen is slightly higher than transmen (60% vs 
40%). Transwomen, who are genetically men, receive estradiol replacement with the aim of suppressing 
serum testosterone and achieving serum estradiol concentrations that mimic the serum concentrations 
of biological women. This leads to an increase in fat mass, breast growth and decreases in lean mass and 
masculine pattern hair. However, the results of these changes are often less than satisfactory and 
additional therapy is required. 
      Breast development is a major concern for transgender females. There is a great deal of variability 
among individuals, as evidenced during pubertal development (2).Transgender women do not achieve 
the same level of breast development as cisgender women do after puberty (3).  Typically, transgender 
women plateau at Tanner stage III and half of the transgender women have a AAA cup size or less (4).  In 
transwomen, breast development is generally maximal at 2 years after initiating hormones (5). 
However, a more recent study of 229 transgender women participating in the European Network for the 
Investigation of Gender Incongruence cohort found that breast development reached a plateau within 
the ﬁrst 6 months of therapy. Half of the transgender women had a AAA cup size or less and only 10% 
were size A or more after a year of treatment (4). Not surprisingly, at least 60% of transgender women 
seek surgical breast augmentation (6).  
    There are transgender females who report an anecdotal improved breast development, mood, or 
sleep with the use of progestogens(7). Estrogen is important for stromal and early ductal and epithelial 
proliferation(2). By contrast, although progesterone in cell culture causes proliferation for a few days, it 
then transforms into its primary, maturational role that includes inhibition of the proliferative effects of 
E2 (7, 8). Progesterone appears to be relevant for acini/lobuli development and pseudolactational 
changes. Many women report a feeling of fullness in breasts and their transformation from a conical to 
more rounded shape (clinical experience of PI). Thus, progesterone may induce optimal breast 
maturation, if preceded by estradiol therapy in transwomen. However, observational studies with small 
number of patients do not support a major role for progesterone in enhancing breast size in 
transwomen (9). There have been no well-designed studies of the role of progestogens in feminizing 
hormone regimens, so the question is still open.  As per Endocrine society transgender guidelines, 
“current evidence does not indicate that progestogens enhance breast development in transgender 
females, nor does evidence prove the absence of such an effect. This prevents us from drawing any firm 
conclusion at this moment and demonstrates the need for further research” (1). 
       Progesterone has a minor suppressive effect on GnRH production, and this would decrease 
endogenous testosterone production. In a chart review, transwomen using medroxyprogesterone (in 
combination with estradiol and spironolactone) had lower testosterone concentrations than those on 
estradiol and spironolactone alone (79 vs 215 ng/dl)(10). Progesterone also competes for the 5-α 
reductase enzyme that converts T into dihydrotestosterone (11). These effects would theoretically be 
desirable in the feminization of transwomen. 
      We plan to conduct a randomized, placebo controlled double blind study evaluating the effect of 
adding progesterone for 6 months to transwomen who are being treated with estradiol. We hypothesize 


that progesterone will decrease serum testosterone concentrations as compared to placebo and 
increase breast size. We will also assess its role in mood, sleep, scalp hair and androgenic hair growth. 
 
Study endpoints: - 
 Serum testosterone concentrations (primary endpoint)  
 Serum luteinizing hormone (LH) and follicle stimulating hormone (FSH) concentrations 
 Breast size  
 Hair growth 
 Sleep quality 
 Mood   
 
Study plan: The study will be conducted by the division of Endocrinology at Saint Louis University. It is a 
randomized, placebo controlled double blind study. We expect to recruit patients from the PI’s 
transgender clinic and from advertisements. 
 
Inclusion criteria 
1. Transwomen, currently on treatment with estradiol therapy for at least 6 months (as their 
standard of care gender affirming therapy)  
2. Has achieved serum estradiol >100 pg/ml at least once, based on clinical labs in past. 
3. Age 18-65 years 
 
Exclusion Criteria 
1. Treatment with progesterone in the last 2 months 
2. HIV 
3. Planning to go for breast enhancement or gender reassignment surgery in the next 6 months 
4. Known history of peanut allergy (because the study drug contains peanut oil)  
5. Active deep vein thrombosis, pulmonary embolism or history of these conditions 
6. Active arterial thromboembolic disease or history of these conditions 
7. Active cardiovascular disorders or history of these conditions (e.g. myocardial infarction, 
uncontrolled hypertension >150/90 mmHg) 
8. Known, suspected, or history of breast cancer 
9. Known liver dysfunction or disease 
10. Known or history of gallbladder disease. This does not apply to subjects who have undergone 
cholecystectomy 
11. Known or history of hypertriglyceridemia (>400 mg/dl) 
 
 
Screening visit: Informed consent will be obtained. This visit may be conducted during the PI’s clinic (if 
the study volunteer is PI’s patient) or at Endocrinology clinical research space at Salus Center. Vital signs 
(blood pressure, heart rate and weight) will be measured and a general physical examination will be 
performed. 


 
Subjects who qualify and consent to take part in the study will be assigned a number by a computerized 
random number generation program and will be randomized (1:1) to receive either progesterone or 
placebo. An unblinded pharmacist will prepare the study product. Study investigators, staff and the 
study participants will be blinded. 
 
Week 0 (baseline): Subjects will come fasting to the Salus Center. Breast exam and testicular exam will 
be conducted. They will complete the study questionnaires. Blood sample will be taken for total 
testosterone, total estradiol, sex hormone binding globulin (SHBG), LH, FSH, complete blood count 
(CBC), comprehensive metabolic panel (CMP) and research labs. For subjects who are on intramuscular 
estradiol, this visit will be performed 3-4 days after their last injection. Subjects will be randomized to 
receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily. They 
will be given a 3-month supply of the study drug. Subjects will be asked to bring the pill bottles back 
with them at the next visit to assess compliance. 
 
Week 4: Subjects will be called by the study coordinator to counsel on drug compliance and to ask for 
side-effects. 
 
Week 12: Subjects will come fasting to the Salus Center. For subjects who are on intramuscular 
estradiol, this visit will be performed 3-4 days after their last injection. Vital signs (blood pressure, heart 
rate and weight) will be measured and a general physical examination will be performed. Blood sample 
will be taken to measure total testosterone, total estradiol, SHBG, LH, FSH and research labs. They will 
complete the study questionnaires. They will be given a 3-month supply of the study drug. Subjects will 
be asked to bring the pill bottles back with them at the next visit. 
 
Week 24 (end of study): Subjects will come fasting to the Salus Center. For subjects who are on 
intramuscular estradiol, this visit will be performed 3-4 days after their last injection. Blood sample will 
be taken to measure CBC, CMP, total testosterone, total estradiol, SHBG, LH, FSH and research labs. Vital 
signs (blood pressure, heart rate and weight) will be measured and a general physical examination will 
be performed. Breast exam and testicular exam will be conducted. They will complete the study 
questionnaires. They will then be discharged from the study. 
 
Study Procedures 
Clinical laboratory assays: All measurements will be carried out by Quest diagnostics as part of a 
standardized contract. We have previously published studies in which measurements of testosterone 
and estradiol on serum samples of our study subjects were done by Quest Diagnostics (12, 13). 
Testosterone and estradiol will be measured by current “gold standard” assay: liquid chromatography 
tandem mass spectrometry. SHBG, FSH and LH concentrations will be measured by a solid-phase, 
chemiluminescent immunometric assay (Siemens, IMMULITE 2500). Free testosterone and estradiol will 
be calculated using concentrations of total testosterone, total estradiol, SHBG and albumin by the 
formula of Sodergard et al and Vermuelen et al (14, 15). 
 


Breast size: The primary measure of breast size will be the difference between breast circumference 
(measured in centimeters with a tape placed horizontally around the thorax over the fullest part of the 
bare breasts) and chest circumference (measured with a flexible tape horizontally placed around the 
thorax in the inframammary fold) (4). Maximal breast hemi-circumference (measured with a flexible 
tape crossing horizontally over the nipple) (9) and areolar diameter will be measured. Investigator will 
note Tanner stage of breast (5). Patients will be asked about feeling of fullness in breast (none, same as 
baseline, more than baseline) and their bra cup size. 
 
Testicular exam: Both testes will be palpated while the subject is standing. Size of each testis will be 
compared against a standard orchidometer. 
 
Hirsutism/hair growth: The degree of androgenic hair growth will be assessed by investigators according 
to the modified Ferriman and Gallwey (FG) scoring system (16, 17). Any shaving, depilation or waxing by 
the patient will be considered in the assessment. Shaving frequency will be recorded as times per week. 
Patients will be asked to rate their scalp hair growth (no change, better than before, worse than before) 
and scalp hair quality (no change, finer than before, coarser than before). 
 
Mood: Subjects will complete two psychometric tests (18):-  
a) Body-image concern questions of Body-uneasiness test (BUT-BIC)(19): This questionnaire has 9 
questions and is meant to capture worries related to physical appearance. Responses are recorded on a 
6 point Likert scale. The mean of all 9 questions is presented as the global severity index. 
b) Symptom-Checklist-K-9 (SCL-K-9) to measure psychological distress level(20): This questionnaire has 9 
questions and is meant to assess overall psychological distress. Responses are recorded on a 5 point 
Likert scale. The mean of all 9 questions is presented as the global severity index. 
 
Sleep quality: We will use single-item sleep quality scale (SQS) to assess change in sleep quality during 
the study.   
FG score calculator and study questionnaires are attached in the IRB application. 
 
Research labs: 10 ml of blood will be obtained for research. Serum will be stored for future analysis 
based on study results. For example, if there is a decrease in FG score, we will check 
dihydrotestosterone levels. 
 
Side effects: Progesterone may cause fluid retention, mood swings, breast tenderness, depression, 
transient dizziness and drowsiness, headache, abdominal pain or bloating, hot flashes in women. Long 
term use is associated with possibly increased risk of heart disease and stroke in women after 
menopause. Short term and long term risks in transwomen are not known. 
If a significant or serious adverse event occurs, the subject will cease participation in the study. 
Discovery of two or more patients experiencing a significant or serious adverse event will lead to 
stopping of this study altogether. 
Statistical analysis: The primary end-point of the study is change in total testosterone concentrations in 
transwomen after progesterone treatment at 24 weeks as compared to placebo. Transformations of the 


data to meet statistical assumptions may be considered. t-test will be used for comparison. We estimate 
that testosterone concentrations will decrease by 20%. A sample size of 20 subjects per group (assuming 
a drop-out rate of 15%) will provide adequate power ( = 0.8) to detect a significant difference ( = 
0.05), provided the pooled standard deviation is not greater than the mean difference. Hence, we will 
recruit 40 transwomen in this study.  
Secondary end-points: Change at weeks 12 and 24 in a) LH and FSH concentrations, b) breast size, breast 
hemi-circumference, areolar diameter, Tanner stage, feeling of fullness in breast, bra cup size, c) FG 
score, shaving frequency, scalp hair growth, scalp hair quality, d) global severity index scores on BUT-BIC 
and SCL-K-9 scales, e) SQS score.      
References 
1. 
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. 
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society 
Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-903. 
2. 
Reisman T, Goldstein Z, and Safer JD. A Review of Breast Development in Cisgender Women and 
Implications for Transgender Women. Endocr Pract. 2019;25(12):1338-45. 
3. 
Sonnenblick EB, Shah AD, Goldstein Z, and Reisman T. Breast Imaging of Transgender 
Individuals: A Review. Curr Radiol Rep. 2018;6(1):1. 
4. 
de Blok CJM, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, et al. Breast Development 
in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective 
Multicenter Study. J Clin Endocrinol Metab. 2018;103(2):532-8. 
5. 
Gooren LJ, Giltay EJ, and Bunck MC. Long-term treatment of transsexuals with cross-sex 
hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19-25. 
6. 
Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclaire C, and Barrett J. Predictive markers for 
mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal 
regimens. J Clin Endocrinol Metab. 2012;97(12):4422-8. 
7. 
Prior JC. Progesterone Is Important for Transgender Women's Therapy-Applying Evidence for 
the Benefits of Progesterone in Ciswomen. J Clin Endocrinol Metab. 2019;104(4):1181-6. 
8. 
Clarke CL, and Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 
1990;11(2):266-301. 
9. 
Meyer WJ, 3rd, Webb A, Stuart CA, Finkelstein JW, Lawrence B, and Walker PA. Physical and 
hormonal evaluation of transsexual patients: a longitudinal study. Arch Sex Behav. 
1986;15(2):121-38. 
10. 
Jain J, Kwan D, and Forcier M. Medroxyprogesterone Acetate in Gender-Affirming Therapy for 
Transwomen: Results From a Retrospective Study. J Clin Endocrinol Metab. 2019;104(11):5148-
56. 
11. 
Bratoeff E, Segura T, Recillas S, Carrizales E, Palacios A, Heuze I, et al. Aromatic esters of 
progesterone as 5alpha-reductase and prostate growth inhibitors. J Enzyme Inhib Med Chem. 
2009;24(3):655-62. 
12. 
Dhindsa S, Furlanetto R, Vora M, Ghanim H, Chaudhuri A, and Dandona P. Low estradiol 
concentrations in men with subnormal testosterone concentrations and type 2 diabetes. 
Diabetes Care. 2011;34(8):1854-9. 
13. 
Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin Resistance 
and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone 
Replacement in Men With Type 2 Diabetes. Diabetes Care. 2016;39(1):82-91. 


14. 
Vermeulen A, Verdonck L, and Kaufman JM. A critical evaluation of simple methods for the 
estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-72. 
15. 
Sodergard R, Backstrom T, Shanbhag V, and Carstensen H. Calculation of free and bound 
fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. 
J Steroid Biochem. 1982;16(6):801-10. 
16. 
Yildiz BO, Bolour S, Woods K, Moore A, and Azziz R. Visually scoring hirsutism. Hum Reprod 
Update. 2010;16(1):51-64. 
17. 
Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, et al. Evaluation and 
Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab. 2018;103(4):1233-57. 
18. 
Fisher AD, Castellini G, Ristori J, Casale H, Cassioli E, Sensi C, et al. Cross-Sex Hormone Treatment 
and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data. J Clin 
Endocrinol Metab. 2016;101(11):4260-9. 
19. 
Marano G, Cuzzolaro M, Vetrone G, Garfinkel PE, Temperilli F, Spera G, et al. Validating the Body 
Uneasiness Test (BUT) in obese patients. Eat Weight Disord. 2007;12(2):70-82. 
20. 
Petrowski K, Schmalbach B, Kliem S, Hinz A, and Brahler E. Symptom-Checklist-K-9: Norm values 
and factorial structure in a representative German sample. PLoS One. 2019;14(4):e0213490.